Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

April 30, 2002

Study Completion Date

July 31, 2002

Conditions
Dyslipidemia
Interventions
DRUG

Muraglitazar

Trial Locations (54)

Unknown

Local Institution, Phoenix

Local Institution, Little Rock

Local Institution, Irvine

Local Institution, Long Beach

Local Institution, Raleigh

Local Institution, Roseville

Local Institution, Sacramento

Local Institution, San Diego

Local Institution, Santa Ana

Local Institution, Longmont

Local Institution, Clearwater

Local Institution, Cooper City

Local Institution, DeLand

Local Institution, Inverness

Local Institution, Longwood

Local Institution, Pembroke Pines

Local Institution, Sarasota

Local Institution, Stuart

Local Institution, Dunwoody

Local Institution, Melbourne

Local Institution, Peoria

Local Institution, Indianapolis

Local Institution, Iowa City

Local Institution, Overland Park

Local Institution, Wichita

Local Institution, Louisville

Local Institution, Marrero

Local Institution, Baltimore

Local Institution, Bethesda

Local Institution, Edina

Local Institution, Minneapolis

Local Institution, Kansas City

Local Institution, St Louis

Local Institution, Toms River

Local Institution, Manlius

Local Institution, Hickory

Local Institution, Winston-Salem

Local Institution, Columbus

Local Institution, Bend

Local Institution, Hillsboro

Local Institution, Portland

Local Institution, Philadelphia

Local Institution, Sellersville

Local Institution, Warminster

Local Institution, Greer

Local Institution, Mt. Pleasant

Local Institution, Austin

Local Institution, Dallas

Local Institution, San Angelo

Local Institution, San Antonio

Local Institution, Olympia

Local Institution, Seattle

Local Institution, Yakima

Local Institution, Ottawa

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY